title: Photodynamic therapy with verteporfin for subfoveal idiopathic choroidal neovascularization: one-year results from a prospective case series.
abstract: OBJECTIVE
  To study the safety and efficacy of photodynamic therapy (PDT) with verteporfin in treating subfoveal choroidal neovascularization (CNV) of idiopathic cause.
  
  
  METHODS
  A prospective, noncomparative, consecutive, open-label, two-center, interventional case series.
  
  
  METHODS
  Patients aged 50 years or younger with the diagnosis of idiopathic CNV by exclusion of other related causes together with the CNV extending under the geometric center of the foveal avascular zone.
  
  
  METHODS
  Seventeen eyes from 17 patients received PDT with verteporfin according to a standardized protocol. Retreatment was considered if fluorescein leakage from the CNV was shown in fluorescein angiography at every 3-month follow-up. The visual, clinical, and angiographic responses were observed. Complications from treatment were monitored and documented.
  
  
  METHODS
  The changes in the best-corrected visual acuity (BCVA) at the 1-year follow-up. The proportion of patients with improved (gained 2 lines or more), stable, and dropped (lost 2 lines or more) vision and the mean number of treatments required during the 1-year interval were measured. Complications were monitored and tabulated.
  
  
  RESULTS
  Seventeen eyes with complete 1-year follow-up were analyzed. The mean logarithm of the minimum angle of resolution BCVA improved from 0.64 to 0.41 (Wilcoxon signed-ranks test, P = 0.007). Sixteen eyes (94%) had stable or improved vision. Only one patient (6%) had moderate loss of vision. The mean number of PDT treatment was 1.8 per eye over the 1-year period. Patients with smaller lesion size or active vascular CNV on presentation were more likely to have a final BCVA of 20/100 or better (Fisher's exact test, P = 0.006 and P = 0.015, respectively). No serious local or systemic complications were encountered.
  
  
  CONCLUSIONS
  PDT seems to be a promising treatment strategy in achieving a stable or improved vision for subfoveal idiopathic CNV. The treatment was well tolerated. Further studies and longer follow-up are warranted to assess the long-term safety and efficacy of PDT compared with observation or other treatment modalities.
authors.affiliation: Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Eye Hospital, Kowloon, Hong Kong, People's Republic of China. cwm6373@netvigator.com
authors.forename: Wai-Man
authors.initials: WM
authors.lastname: Chan
authors.forename: Dennis S C
authors.initials: DS
authors.lastname: Lam
authors.forename: Tak-Hung
authors.initials: TH
authors.lastname: Wong
authors.forename: Timothy Y Y
authors.initials: TY
authors.lastname: Lai
authors.forename: Alvin K H
authors.initials: AK
authors.lastname: Kwok
authors.forename: Barbara S M
authors.initials: BS
authors.lastname: Tam
authors.forename: Kenneth K W
authors.initials: KK
authors.lastname: Li
mesh_terms: D000328:Adult; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D005451:Fluorescein Angiography; D005584:Fovea Centralis; D006801:Humans; D008297:Male; D008875:Middle Aged; D010778:Photochemotherapy; D017319:Photosensitizing Agents / Q000627:therapeutic use*; D011166:Porphyrins / Q000627:therapeutic use*; D011446:Prospective Studies; D012449:Safety; D016896:Treatment Outcome; D000077362:Verteporfin; D014792:Visual Acuity
chemical_list: D017319:Photosensitizing Agents; D011166:Porphyrins; D000077362:Verteporfin